CEO: David A. Giljohann
Headquarters: Skokie, Illinois
Investment Date: September 2017
APO Financing: $31,500,000
Trading Venue: OTCQB (XCUR)
Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.